Terumo Corporation · Fiscal year ended March 2026
Measure, inject, navigate, circulate: Terumo's ¥1.13 trillion century.
Terumo began with one basic act: measuring body temperature. FY2025 revenue reached ¥1.1319 trillion, and the company's largest field is now Cardiac and Vascular. Blood and Cell Technologies and Medical Care Solutions are also major businesses. The interesting shift is not simply that Terumo added more products. Over a century, its role moved from measuring the body to entering vessels, handling blood and supporting circulation.
This is not investment advice or a stock recommendation. We reorder company-published primary-source facts to make the shape of the business easier to see.
Terumo began with a thermometer.
Today it works across the heart, blood vessels, blood, cells and drug delivery.
A thermometer form, flexible tubing and a hollow-fiber material study interpret deeper clinical involvement. Not an actual medical circuit, product specification or claim about treatment outcomes.
Revenue is ¥1.1319 trillion
The largest field is Cardiac and Vascular.
Cardiac and Vascular is ¥676.4bn
Blood and Cell Technologies is another major pillar.
Blood and Cell Technologies is ¥231.0bn
The company also retains businesses closer to hospital care and drug delivery.
Medical Care Solutions is ¥216.1bn
Terumo now reaches deep into the body
FY2025 revenue in its major operating fields.
The business is also highly international.
The Americas represent 39%
That makes the starting point look surprisingly modest.
It began with thermometers in 1921
The next major problem was not measurement, but infection.
Single-use syringes in the 1960s
Then came technology that handled blood outside the body.
An oxygenator in 1982
The company then moved directly into vessels.
Angiographic catheters in 1985
Even the founding product was not preserved forever.
Artificial organs in 1977
Measure.
Inject.
Handle blood.
Navigate vessels.
Support circulation.
The products look very different, but the sequence is continuous when read as a deeper involvement in clinical care.
THE VIEW AFTER THE NUMBERS
What the numbers suggest
Terumo generated ¥1.1319 trillion of revenue in FY2025.
Cardiac and Vascular generated ¥676.4 billion, Blood and Cell Technologies ¥231.0 billion, and Medical Care Solutions ¥216.1 billion.
The company began in 1921 with thermometers.
It moved into single-use syringes in the 1960s, a dialyzer in 1977, an oxygenator in 1982, and angiographic catheters in 1985.
Terumo did not suddenly leave thermometers behind and become a cardiovascular company.
It kept moving from measuring to injecting, navigating vessels and supporting circulation as the clinical problems it addressed became deeper and more complex.
Primary sources used
Financial Results for the Fiscal Year Ended March 31, 2026 (FY2025)
Terumo Corporation · 2026-05-15
Pages used: p.4 / p.8 / p.9 / p.10 / p.12
Open source →Terumo Corporate Guide 2025
Terumo Corporation
Pages used: p.22
Open source →